Randomized study of single-dose, three-day, and seven-day treatment of cystitis in women

Richard N. Greenberg; Patrick M. Reilly; Kevin L. Luppen; William J. Weinandt; Lisa L. Ellington; Margaret R. Bollinger

doi:10.1093/infdis/153.2.277

Randomized study of single-dose, three-day, and seven-day treatment of cystitis in women

Richard N. Greenberg
, Patrick M. Reilly
, Kevin L. Luppen
, William J. Weinandt
, Lisa L. Ellington
, Margaret R. Bollinger

Internal Medicine

Producción científica: Article › revisión exhaustiva

52 Citas (Scopus)

Resumen

Weevaluated the following five treatment regimens for acute cystitis in nonpregnant women: cefadroxil, 1, 000 mg single-dose; cefadroxil, 500 mg twice a day for three days; cefadroxil, 500 mg twice a day for seven days; trimethoprim-sulfamethoxazole (TMP-SMZ), 320–1, 600 mg single-dose, and TMP-SMZ, 160–800 mg twice a day for three days. At four weeks after the end of treatment, 25%, 58%, 70%, 65%, and 88% of patients, respectively, remained cured of infection. The results indicated that three-day treatment (1) might improve cure rates (over single-dose), (2) would reduce incidence of relapse (vs. single-dose), and (3) may be as curative as seven-day treatment. The results of the antibody-coated bacteria test did not predict treatment failure or relapse.

Idioma original	English
Páginas (desde-hasta)	277-282
Número de páginas	6
Publicación	Journal of Infectious Diseases
Volumen	153
N.º	2
DOI	https://doi.org/10.1093/infdis/153.2.277
Estado	Published - feb 1986

Nota bibliográfica

Funding Information:
Received for publication 21 May 1985, and in revised form 27 August 1985. This study was funded in part by a grant from Bristol Research Laboratories. We thank the nurse practitioners at St. Louis City Hospital; the following emergency room and clinic physicians for patient referrals: Drs. Antworth, Cometa, Devera, Hochreiter, Kulkamthorn, Lamb, Malano, Marino, Ronnau, Schlitchtig, Smith, Silver, and Punjabi; and Sue Stevens and Anita Boone for their secretarial assistance. The laboratory of Dr. Richard A. Wilson, Director of the Escherichia coli Reference Center, Department of Veterinary Science, Pennsylvania State University, kindly performed E. coli serotyping. Please address requests for reprints to Dr. Richard Greenberg, Divisionof Infectious Diseases, Department of Medicine, St. Louis University School of Medicine, 1402 South Grand Avenue, St. Louis, Missouri 63104.

Financiación

Received for publication 21 May 1985, and in revised form 27 August 1985. This study was funded in part by a grant from Bristol Research Laboratories. We thank the nurse practitioners at St. Louis City Hospital; the following emergency room and clinic physicians for patient referrals: Drs. Antworth, Cometa, Devera, Hochreiter, Kulkamthorn, Lamb, Malano, Marino, Ronnau, Schlitchtig, Smith, Silver, and Punjabi; and Sue Stevens and Anita Boone for their secretarial assistance. The laboratory of Dr. Richard A. Wilson, Director of the Escherichia coli Reference Center, Department of Veterinary Science, Pennsylvania State University, kindly performed E. coli serotyping. Please address requests for reprints to Dr. Richard Greenberg, Divisionof Infectious Diseases, Department of Medicine, St. Louis University School of Medicine, 1402 South Grand Avenue, St. Louis, Missouri 63104.

Financiadores
Bristol Research Laboratories

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Acceder al documento

10.1093/infdis/153.2.277

Otros archivos y enlaces

Citar esto

@article{c4e68172f1ce495e8bb82a0b41aa6da6,

title = "Randomized study of single-dose, three-day, and seven-day treatment of cystitis in women",

abstract = "Weevaluated the following five treatment regimens for acute cystitis in nonpregnant women: cefadroxil, 1, 000 mg single-dose; cefadroxil, 500 mg twice a day for three days; cefadroxil, 500 mg twice a day for seven days; trimethoprim-sulfamethoxazole (TMP-SMZ), 320–1, 600 mg single-dose, and TMP-SMZ, 160–800 mg twice a day for three days. At four weeks after the end of treatment, 25\%, 58\%, 70\%, 65\%, and 88\% of patients, respectively, remained cured of infection. The results indicated that three-day treatment (1) might improve cure rates (over single-dose), (2) would reduce incidence of relapse (vs. single-dose), and (3) may be as curative as seven-day treatment. The results of the antibody-coated bacteria test did not predict treatment failure or relapse.",

author = "Greenberg, \{Richard N.\} and Reilly, \{Patrick M.\} and Luppen, \{Kevin L.\} and Weinandt, \{William J.\} and Ellington, \{Lisa L.\} and Bollinger, \{Margaret R.\}",

note = "Funding Information: Received for publication 21 May 1985, and in revised form 27 August 1985. This study was funded in part by a grant from Bristol Research Laboratories. We thank the nurse practitioners at St. Louis City Hospital; the following emergency room and clinic physicians for patient referrals: Drs. Antworth, Cometa, Devera, Hochreiter, Kulkamthorn, Lamb, Malano, Marino, Ronnau, Schlitchtig, Smith, Silver, and Punjabi; and Sue Stevens and Anita Boone for their secretarial assistance. The laboratory of Dr. Richard A. Wilson, Director of the Escherichia coli Reference Center, Department of Veterinary Science, Pennsylvania State University, kindly performed E. coli serotyping. Please address requests for reprints to Dr. Richard Greenberg, Divisionof Infectious Diseases, Department of Medicine, St. Louis University School of Medicine, 1402 South Grand Avenue, St. Louis, Missouri 63104.",

year = "1986",

month = feb,

doi = "10.1093/infdis/153.2.277",

language = "English",

volume = "153",

pages = "277--282",

number = "2",

}

TY - JOUR

T1 - Randomized study of single-dose, three-day, and seven-day treatment of cystitis in women

AU - Greenberg, Richard N.

AU - Reilly, Patrick M.

AU - Luppen, Kevin L.

AU - Weinandt, William J.

AU - Ellington, Lisa L.

AU - Bollinger, Margaret R.

N1 - Funding Information: Received for publication 21 May 1985, and in revised form 27 August 1985. This study was funded in part by a grant from Bristol Research Laboratories. We thank the nurse practitioners at St. Louis City Hospital; the following emergency room and clinic physicians for patient referrals: Drs. Antworth, Cometa, Devera, Hochreiter, Kulkamthorn, Lamb, Malano, Marino, Ronnau, Schlitchtig, Smith, Silver, and Punjabi; and Sue Stevens and Anita Boone for their secretarial assistance. The laboratory of Dr. Richard A. Wilson, Director of the Escherichia coli Reference Center, Department of Veterinary Science, Pennsylvania State University, kindly performed E. coli serotyping. Please address requests for reprints to Dr. Richard Greenberg, Divisionof Infectious Diseases, Department of Medicine, St. Louis University School of Medicine, 1402 South Grand Avenue, St. Louis, Missouri 63104.

PY - 1986/2

Y1 - 1986/2

N2 - Weevaluated the following five treatment regimens for acute cystitis in nonpregnant women: cefadroxil, 1, 000 mg single-dose; cefadroxil, 500 mg twice a day for three days; cefadroxil, 500 mg twice a day for seven days; trimethoprim-sulfamethoxazole (TMP-SMZ), 320–1, 600 mg single-dose, and TMP-SMZ, 160–800 mg twice a day for three days. At four weeks after the end of treatment, 25%, 58%, 70%, 65%, and 88% of patients, respectively, remained cured of infection. The results indicated that three-day treatment (1) might improve cure rates (over single-dose), (2) would reduce incidence of relapse (vs. single-dose), and (3) may be as curative as seven-day treatment. The results of the antibody-coated bacteria test did not predict treatment failure or relapse.

AB - Weevaluated the following five treatment regimens for acute cystitis in nonpregnant women: cefadroxil, 1, 000 mg single-dose; cefadroxil, 500 mg twice a day for three days; cefadroxil, 500 mg twice a day for seven days; trimethoprim-sulfamethoxazole (TMP-SMZ), 320–1, 600 mg single-dose, and TMP-SMZ, 160–800 mg twice a day for three days. At four weeks after the end of treatment, 25%, 58%, 70%, 65%, and 88% of patients, respectively, remained cured of infection. The results indicated that three-day treatment (1) might improve cure rates (over single-dose), (2) would reduce incidence of relapse (vs. single-dose), and (3) may be as curative as seven-day treatment. The results of the antibody-coated bacteria test did not predict treatment failure or relapse.

UR - https://www.scopus.com/pages/publications/0022640668

UR - https://www.scopus.com/pages/publications/0022640668#tab=citedBy

U2 - 10.1093/infdis/153.2.277

DO - 10.1093/infdis/153.2.277

M3 - Article

C2 - 3484773

AN - SCOPUS:0022640668

SN - 0022-1899

VL - 153

SP - 277

EP - 282

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 2

ER -

Randomized study of single-dose, three-day, and seven-day treatment of cystitis in women

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto